The title compound [systematic name: 3-(10,11-dihydro-5H-dibenzo À , a maleate salt of trimipramine, crystallizes with four independent cation-anion pairs in the asymmetric unit. The trimipramine cation contains a seven-membered azepine ring with two fused benzene rings whose mean planes are separated by 51.7 (1) . Intermolecular N-HÁ Á ÁO and intramolecular O-HÁ Á ÁO hydrogen bonds pack the ions into chains along [101] . Additional weak intermolecular C-HÁ Á ÁO interactions help to influence the twist angles of the mean planes of the benzene rings fused to the azepine ring in the cation. A geometry-optimized MOPAC AM1 theoretical calculation supports these observations.
Related literature
For refractory depression treatment, see : Broquet, (1999) 
has failed to respond to standard SSRI therapy (Broquet, 1999) . Tricyclic antidepressants have been shown to be effective in treating attention-deficit hyperactivity disorder(ADHD) (Biederman et al., 1989) . ADHD is thought to be caused by dopamine and norepinephrine shortages in the brain's prefrontal cortex.
Trimipramine is a tricyclic antidepressant of the dibenzazepine class with sedative properties. It also has anticholinergic properties and potentiates the sympathetic response, presumably by blocking the reuptake of norepinephrine which has been released by the presynaptic neurons. It has a quinidine like effect on the heart and an EEG activity similar to that of other tricyclic antidepressants. Trimipramine is a serotonin transport blocker that also blocks norepinephrine uptake. The mechanism of action of trimipramine differs from other tricyclic antidepressants. It is only a moderate reuptake inhibitor of norepinephrine, and a weak reuptake inhibitor of serotonin and dopamine. The spectrum of effects (strong antidepressant activity, sedation and anxiolysis) and side-effects (strong anticholinergic and antiadrenergic side-effects) is the same as with Doxepin. It is also a more effective sedative than amitriptyline. Trimipramine is the only effective drug against insomnia known so far that does not alter the normal sleep architecture.
Trimipramine maleate salt is used in the treatment of depression as well as peptic ulcer and severe chronic pain. A comprehensive description of the title compound is described (Al-Badr, 1983; Lapierre, 1989 (Somashekar et al., 2004) . Also, the PMR spectrometric analysis of trimipramine maleate in pharmaceutical preparation is described (Al-Badr & Ibrahim, 1979) . The related crystal structures viz., imipramine hydrochloride (Post et al., 1975), 5-(3- (Jones et al., 1978) , desipraminium picrate (Swamy et al., 2007) , desipraminium picrate monohydrate (Harrison, Swamy et al., 2007) , imipraminium picrate (Harrison, Bindya et al., 2007) , amitriptylinium picrate (Bindya et al., 2007), 5-[3-(dimethylamino) propyl]-10,11-dihydro-5H-dibenz [a,d] [7]annulen-5-ol (Portalone et al., 2007) have been reported. In view of the importance of the title compound, a crystal structure is reported. , respectively. These angles are all less than 57;1(1)° reported for bis (3) (4) (5) (6) (7) (8) (9) (10) f) azepin-5-yl)-2-methyl-propyl) dimethylammonium) tetrachlorocuprate(ii) (Kamel et al. 2001) , which contains an identical cation.
Intermolecular N-H···O and intramolecular O-H···O hydrogen bonds ( These observations support the suggestion that these intra and intermolecular interactions influence crystal packing in the title compound.
Experimental
The title compound was obtained as a gift sample from R. L. Fine Chem, Bangalore, India. The compound was used without further purification. X-ray quality crystals (m.p. 410-412 K) were obtained by slow evaporation from methanol solution.
Refinement
All of the H atoms were placed in their calculated positions and then refined using the riding model with O-H = 0.84 Å, N-H = 0.93 Å, C-H = 0.95-1.00 Å, and with U iso (H) = 1.19-2.23U eq (O), U iso (H) = 1.18-1.21 eq (N), U iso (H) = 1.18-1.51U eq (C). 
